Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia

被引:19
作者
Badawi, Yomna [1 ,2 ]
Shi, Honglian [1 ,2 ]
机构
[1] Univ Kansas, Neurosci Program, Lawrence, KS 66045 USA
[2] Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA
来源
FRONTIERS IN NEUROSCIENCE | 2017年 / 11卷
基金
美国国家卫生研究院;
关键词
oxidative stress; proteasome; stroke; neurons; HIF-1; HYPOXIA-INDUCIBLE FACTOR; BRAIN-INJURY; INHIBITOR MLN519; IN-VIVO; LEUKOCYTE INFILTRATION; REDUCES INFARCTION; DELAYED TREATMENT; ARTERY OCCLUSION; GENE-EXPRESSION; FOCAL ISCHEMIA;
D O I
10.3389/fnins.2017.00239
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Hypoxia inducible factor-1 (HIF-1) is a key regulator in hypoxia and can determine the fate of brain cells during ischemia. However, the mechanism of HIF-1 regulation is still not fully understood in ischemic brains. We tested a hypothesis that both the 26S and the 20S proteasomal pathways were involved in HIF-1 alpha degradation under ischemic conditions. Using in vitro ischemic model (oxygen and glucose deprivation) and a mouse model of middle cerebral artery occlusion, we tested effects of inhibitors of proteasomes and prolyl hydroxylase (PHD) on HIP-1 alpha stability and brain injury in cerebral ischemia. We observed that 30 and 60 min of oxygen-glucose deprivation significantly increased the 20S proteasomal activity. We demonstrated that proteasome inhibitors increased HIF-1 alpha stabilization and cell viability and were more effective than PHD inhibitors in primary cultured cortical neurons exposed to oxygen and glucose deprivation. Furthermore, the administration of the proteasome inhibitor, epoxomicin, to mice resulted in smaller infarct size and brain edema than a PHD inhibitor. Our results indicate that 20S proteasomes are involved in HIF-1 alpha degradation in ischemic neurons and that proteasomal inhibition provides more HIP-1 alpha stabilization and neuroprotection than PHD inhibition in cerebral ischemia.
引用
收藏
页数:9
相关论文
共 54 条
  • [1] Neuron-specific inactivation of the hypoxia inducible factor 1α increases brain injury in a mouse model of transient focal cerebral ischemia
    Baranova, Oxana
    Miranda, Luis F.
    Pichiule, Paola
    Dragatsis, Ioannis
    Johnson, Randall S.
    Chavez, Juan C.
    [J]. JOURNAL OF NEUROSCIENCE, 2007, 27 (23) : 6320 - 6332
  • [2] Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat
    Berti, R
    Williams, AJ
    Velarde, LC
    Moffett, JR
    Elliott, PJ
    Adams, J
    Yao, C
    Dave, JR
    Tortella, FC
    [J]. NEUROTOXICITY RESEARCH, 2003, 5 (07) : 505 - 514
  • [3] Regulation of proteasome-mediated protein degradation during oxidative stress and aging
    Breusing, Nicolle
    Grune, Tillman
    [J]. BIOLOGICAL CHEMISTRY, 2008, 389 (03) : 203 - 209
  • [4] Clark WM, 1997, NEUROL RES, V19, P641
  • [5] Structure and functions of the 20S and 26S proteasomes
    Coux, O
    Tanaka, K
    Goldberg, AL
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1996, 65 : 801 - 847
  • [6] Degradation of oxidized proteins by the 20S proteasome
    Davies, KJA
    [J]. BIOCHIMIE, 2001, 83 (3-4) : 301 - 310
  • [7] Accumulation of hypoxia-inducible factor-1α is limited by transcription-dependent depletion
    Demidenko, ZN
    Rapisarda, A
    Garayoa, M
    Giannakakou, P
    Melillo, G
    Blagosklonny, MV
    [J]. ONCOGENE, 2005, 24 (30) : 4829 - 4838
  • [8] The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis
    Doeppner, Thorsten R.
    Mlynarczuk-Bialy, Izabela
    Kuckelkorn, Ulrike
    Kaltwasser, Britta
    Herz, Josephine
    Hasan, Mohammad R.
    Hermann, Dirk M.
    Baehr, Mathias
    [J]. BRAIN, 2012, 135 : 3282 - 3297
  • [9] C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation
    Epstein, ACR
    Gleadle, JM
    McNeill, LA
    Hewitson, KS
    O'Rourke, J
    Mole, DR
    Mukherji, M
    Metzen, E
    Wilson, MI
    Dhanda, A
    Tian, YM
    Masson, N
    Hamilton, DL
    Jaakkola, P
    Barstead, R
    Hodgkin, J
    Maxwell, PH
    Pugh, CW
    Schofield, CJ
    Ratcliffe, PJ
    [J]. CELL, 2001, 107 (01) : 43 - 54
  • [10] Anthracyclines, proteasome activity and multi-drug-resistance
    Fekete, MR
    McBride, WH
    Pajonk, F
    [J]. BMC CANCER, 2005, 5 (1)